Bradley Merrill Thompson Quoted in “FDA Issues Regulatory Science Priorities”POLITICO Morning eHealth October 21, 2015
Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in POLITICO’s Morning eHealth, in “FDA Issues Regulatory Science Priorities.”
Following is an excerpt:
The agency also discusses use of more computer modeling to catch risky ideas before they become things, among other cool tech ideas.
But perhaps they'll only remain cool tech ideas. Epstein Becker & Green lawyer Bradley Thompson, who specializes in digital health issues, is a bit skeptical of the rollout. "I wish I could say that I've seen these agency research initiatives pay dividends in terms of increasing the speed of FDA review, but I haven't," he writes us. Thompson would instead prefer more effort to get guidances out the door.